Health CanadaGeneral Alert
SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogr...
Published: October 25, 2016Recall ID: 55712Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination
Additional Source Details
| Field | Value |
|---|---|
| N I D | 55712 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/soliris-eculizumab-increased-risk-hemolysis-or-low-hemoglobin-serogroup-b |
| Issue | Product safety |
| Title | SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination |
| Archived | 1 |
| Category | Biologic or vaccine |
| Last updated | 2016-10-25 |
| Organization | Marketed health products |